Literature DB >> 28508963

Hemodiafiltration for hepatic encephalopathy induced by Budd-Chiari syndrome in a patient with end-stage kidney disease.

Takuya Wakamatsu1, Suguru Yamamoto2, Kenya Kamimura3, Takeshi Nakatsue1, Noriaki Iino1, Seitaro Iguchi4, Yoshikatsu Kaneko1, Shin Goto1, Junichiro James Kazama5, Ichiei Narita1.   

Abstract

A 36-year-old woman who was undergoing dialysis for end-stage kidney disease (ESKD) was admitted to our hospital with consciousness disorder. She was diagnosed with Budd-Chiari syndrome due to antiphospholipid syndrome at the age of 28 years. Her kidney function and leg edema gradually deteriorated. After initiation of hemodialysis (HD), transient loss of consciousness due to hepatic encephalopathy during HD treatment occurred frequently. Her kidney replacement therapy was changed to online hemodiafiltration (HDF), which dramatically improved her hepatic coma. Compared with HD, HDF contributed to the increase in Fischer's ratio and decrease in tryptophan level, which has a high protein-bound property. This case suggests that HDF may be beneficial for hepatic encephalopathy in ESKD patients by modulating the amino acid profile.

Entities:  

Keywords:  Budd–Chiari syndrome; Fischer’s ratio; Hemodiafiltration; Hepatic encephalopathy; Portal-systemic shunt

Year:  2015        PMID: 28508963      PMCID: PMC5413750          DOI: 10.1007/s13730-015-0209-7

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  21 in total

1.  Continuous removal of middle molecules by hemofiltration in patients with acute liver failure.

Authors:  S Matsubara; K Okabe; K Ouchi; Y Miyazaki; Y Yajima; H Suzuki; M Otsuki; S Matsuno
Journal:  Crit Care Med       Date:  1990-12       Impact factor: 7.598

Review 2.  Push/pull hemodiafiltration.

Authors:  Toru Shinzato; Kenji Maeda
Journal:  Contrib Nephrol       Date:  2007       Impact factor: 1.580

3.  Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient.

Authors:  Chang Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew; Sei Jong Kim
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

4.  Acute renal failure due to bilateral renal artery thrombosis associated with primary antiphospholipid syndrome.

Authors:  R Rysavá; J Zabka; J H Peregrin; V Tesar; M Merta; I Rychlik
Journal:  Nephrol Dial Transplant       Date:  1998-10       Impact factor: 5.992

5.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Authors:  Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong
Journal:  Hepatology       Date:  2014-07-08       Impact factor: 17.425

6.  On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations.

Authors:  W Lornoy; I Becaus; J M Billiouw; L Sierens; P Van Malderen; P D'Haenens
Journal:  Nephrol Dial Transplant       Date:  2000       Impact factor: 5.992

7.  Outcomes of hemodiafiltration based on Japanese dialysis patient registry.

Authors:  S Nakai; K Iseki; K Tabei; K Kubo; I Masakane; K Fushimi; K Kikuchi; T Shinzato; T Sanaka; T Akiba
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

Review 8.  Hepatic encephalopathy.

Authors:  Santiago J Munoz
Journal:  Med Clin North Am       Date:  2008-07       Impact factor: 5.456

9.  Role of tryptophan in the pathogenesis of hepatic encephalopathy.

Authors:  Darakhshan M Saleem; Saida Haider; Moona M Khan; Tahir Shamsi; Darakhshan J Haleem
Journal:  J Pak Med Assoc       Date:  2008-02       Impact factor: 0.781

Review 10.  Budd-Chiari syndrome and renal failure in Behcet disease. Report of a case and review of the literature.

Authors:  D Wilkey; D E Yocum; T D Oberley; W R Sundstrom; L Karl
Journal:  Am J Med       Date:  1983-09       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.